Outlook Therapeutics at H.C. Wainwright: launch hinges on access
On Friday, September 11th, 2026, Outlook Therapeutics (OTLK) presented their commercial strategy at the H.C. Wainwright 28th Annual Global Investment Conference, centered around their newly FDA-approved eye drug LYTENAVA. Chief Executive Bob Jahr highlighted that the FDA approval allows the company to shift from an off-label market to a regulated ophthalmic product, offering manufacturing support, patient services and billing code.
The launch, Jahr emphasized, hinges on payer access, practice readiness, and a permanent J-code expected in 2027. Outlook Therapeutics is targeting a sizeable but mature market, with approximately 2.2 million repackaged bevacizumab injections administered annually in the U.S. The company is aiming to price LYTENAVA under $500 per dose to foster broad payer access and patient affordability.
A permanent J-code, scheduled for April 1, 2027, will be crucial for wider adoption, according to Jahr. The FDA approval represents the company's central mission: introducing the first ophthalmic FDA-approved bevacizumab for wet age-related macular degeneration. Outlook acknowledges the challenges ahead, such as reimbursement delays, pricing pressure, and slow adoption.
The company is taking a selective launch approach, focusing on practices most dissatisfied with repackaged bevacizumab, rather than a broad sales-force rollout.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
